Biogen News

Scientists at the Alzheimer's Association International Conference in London have reported encouraging results in testing for and reducing levels of tau protein

An experimental Alzheimer's drug, diranersen, has shown potential in slowing cognitive decline by targeting the tau protein, according to new research presented

The US FDA has approved an at-home starter dose for Eisai and Biogen's Alzheimer's drug, Leqembi, allowing patients to self-administer subcutaneous injections.